ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,192Medicare Part D Prescriptions Filled, Including Refills

Rank: 8 out of 122

$584K Total Retail Price of All Prescriptions

Rank: 9 out of 122

450 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

15% of this provider’s 450 patients filled at least one prescription for a schedule two drug, compared to an average of 10%.

Schedule Three
Controlled Substances

8% of this provider’s 450 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

2% of this provider’s 7,480 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
SIMVASTATIN 377 319 1 1
LISINOPRIL 347 303 2 2
LEVOTHYROXINE SODIUM 271 257 3 4
FUROSEMIDE 264 207 4 5
OMEPRAZOLE 263 242 5 3
METOPROLOL TARTRATE 251 234 6 8
WARFARIN SODIUM 221 162 7 9
TRAMADOL HCL 201 145 8 20
AMLODIPINE BESYLATE 180 172 9 7
ZOLPIDEM TARTRATE 168 143 10 19
ATENOLOL 167 167 11 10
HYDROCHLOROTHIAZIDE 152 132 12 6
LOSARTAN POTASSIUM 149 129 13 17
PREDNISONE 145 126 14 24
GABAPENTIN 139 106 15 12
ATORVASTATIN CALCIUM 137 115 16 13
CITALOPRAM HBR 135 123 17 15
HYDROCODONE-ACETAMINOPHEN 123 118 S3 18 16
SERTRALINE HCL 118 87 19 18
LANTUS 98 66 20 36
OXYCONTIN 96 69 S2 21 87
OXYCODONE HCL 93 43 S2 22 30
METFORMIN HCL 87 73 23 14
ALLOPURINOL 83 73 24 33
NOVOLOG 80 62 25 115
ADVAIR DISKUS 79 74 26 34
ESCITALOPRAM OXALATE 78 66 27 59
RANITIDINE HCL 77 71 28 39
QUETIAPINE FUMARATE 76 69 29 46
CYMBALTA 73 18 30 62
TRAZODONE HCL 72 46 31 21
PROAIR HFA 69 45 32 31
PANTOPRAZOLE SODIUM 65 47 33 23
DONEPEZIL HCL 63 63 34 25
ALENDRONATE SODIUM 62 58 35 35
BACLOFEN 61 0 36 119
CEPHALEXIN 61 61 36 109
SPIRIVA 60 43 38 29
CRESTOR 60 60 38 37
LIDODERM 57 42 40 129
METOPROLOL SUCCINATE 57 48 40 11
JANUVIA 57 52 40 78
GLIMEPIRIDE 56 56 43 51
OXYCODONE-ACETAMINOPHEN 55 43 S2 44 41
MORPHINE SULFATE ER 54 26 S2 45 42
FLUTICASONE PROPIONATE 54 36 45 49
FENTANYL 52 29 S2 47 47
ISOSORBIDE MONONITRATE ER 50 50 48 44
MIRTAZAPINE 50 40 48 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 20, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.